Partnership for Safe Medicines Applauds Senate HELP Committee Vote to Table Harmful Drug Importation Amendment But Remains Concerned About Current Importation Proposals

Washington, DC (June 17, 2022) – Shabbir Safdar, executive director of The Partnership for Safe Medicines, released the following statement today: “The U.S. Senate Committee on Health, Education, Labor & Pensions’ 15-7 vote against Senator Sanders’ foreign drug importation amendment to S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, is…

[...]

FDA Alert: Dietary Supplement Marketed for Pain Relief Recalled Due to Presence of Diclofenac and Dexamethasone

Consumption of undeclared diclofenac could result in serious adverse events that include cardiovascular, gastrointestinal, renal, and anaphylaxis in patients taking concomitant NSAIDs and/or anticoagulants, in those who have allergies to diclofenac, or those with underlying illnesses. Consumption of undeclared dexamethasone may lead to severe and serious adverse events such as adrenal suppression, a disorder in which the adrenal glands do not produce enough hormones, and adverse consequences can range from limited adverse consequences to death.

[...]

Partnership for Safe Medicines Statement on Foreign Drug Importation Efforts in the U.S. Senate (updated)

Washington, D.C. (Updated June 13, 2022) – Shabbir Imber Safdar, executive director of the Partnership for Safe Medicines, released the following statement in advance of the Senate HELP Committee’s June 14th Executive Session. “The amendments offered to include foreign drug importation in S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, are…

[...]

Director of Health and Science Policy at Citizens Against Government Waste Calls Drug Importation Dangerous

Instead of wasting time and money on dangerous and faulty importation proposals, Congress should encourage the FDA to speed up the drug approval process and reduce the cost of program and application fees for future drug development. In 2022, the application fee for a human drug application will cost $1.6 million for drugs that don’t require clinical data and $3.1 million for medicines that do need clinical data.

[...]